Literature DB >> 26274993

Anaplastic meningioma: octreotide therapy for a case of recurrent and progressive intracranial disease.

Richard Rammo1, Adam Rock2, Andrea Transou1, Aditya Raghunathan3, Jack Rock1.   

Abstract

Meningiomas are common intracranial tumors categorized as Grades I-III per the current WHO guidelines. A small percentage of meningiomas are Grades II and III, which are likely to recur after initial treatment. Grade III meningiomas are considered to be malignant and warrant aggressive management. If surgery and radiation fail to produce lasting remission, effective treatment options for patients with progressive anaplastic meningiomas are elusive. The authors present the case of a patient with a meningioma that gradually progressed from Grade I to Grade III over 12 years despite repeated surgery and radiation therapy. The patient has been in remission for over 3 years following octreotide therapy.

Entities:  

Keywords:  PBS = phosphate-buffered saline; SST = somatostatin receptor; intracranial; meningioma; octreotide; oncology

Mesh:

Substances:

Year:  2015        PMID: 26274993     DOI: 10.3171/2015.1.JNS142260

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  5 in total

Review 1.  Somatostatin analogues in treatment-refractory meningioma: a systematic review with meta-analysis of individual patient data.

Authors:  Lasse Rehné Jensen; Andrea Daniela Maier; Atle Lomstein; Thomas Graillon; Maya Hrachova; Daniela Bota; Alejandro Ruiz-Patiño; Oscar Arrieta; Andrés Felipe Cardona; Roberta Rudà; Julia Furtner; Ulrich Roeckle; Paul Clement; Matthias Preusser; David Scheie; Helle Broholm; Bjarne Winther Kristensen; Jane Skjøth-Rasmussen; Morten Ziebell; Tina Nørgaard Munch; Kåre Fugleholm; Martin A Walter; Tiit Mathiesen; Christian Mirian
Journal:  Neurosurg Rev       Date:  2022-08-19       Impact factor: 2.800

2.  Prognostic factors for patients with World Health Organization grade III meningiomas treated at a single center.

Authors:  Baoyin Shan; Jing Zhang; Yanlin Song; Jianguo Xu
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

3.  A rare subtype of meningioma: Case series of anaplastic meningioma and review of the literature.

Authors:  Hongyi Cao; Biying Jiang; Yang Zhao; Chuifeng Fan
Journal:  Medicine (Baltimore)       Date:  2018-06       Impact factor: 1.889

4.  SSTR-2 as a potential tumour-specific marker for fluorescence-guided meningioma surgery.

Authors:  B M Dijkstra; A Motekallemi; W F A den Dunnen; J R Jeltema; G M van Dam; F A E Kruyt; R J M Groen
Journal:  Acta Neurochir (Wien)       Date:  2018-06-01       Impact factor: 2.216

Review 5.  Emerging Medical Treatments for Meningioma in the Molecular Era.

Authors:  Fares Nigim; Hiroaki Wakimoto; Ekkehard M Kasper; Linda Ackermans; Yasin Temel
Journal:  Biomedicines       Date:  2018-08-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.